They just submitted the application of bonus issue to Bursa. Waiting for approval.
On behalf of Bioalpha, TA Securities wishes to announce that an application to Bursa Securities for the listing of and quotation for the Bonus Shares and SIS Shares on the ACE Market of Bursa Securities has been submitted on 6 June 2016.
FDL Technology Sdn Bhd, a MSC status company, is established in Year 2014 with commitment in providing turn-key solutions for your e-Commerce supply chain from online to offline total solutions platform to drive modern retailing industries via online sales channel. FDL experts create an optimal design based on your needs and then implement that design, planning, train your staff and provide round-the-clock customer service and technical support.
Throughout several years in the industries, FDL have received recognition from many established local & MNC companies and enabling FDL toward rapid growth in 3RD Party e-Commerce Fulfilment Centre Operation and supply chain turn key solutions.
FDL mission statement is to consolidate all potential e-Commerce companies in Malaysia and improve the overall offline fulfilment experience in order to provide best consumer online shopping experience.
16.10.2014 | DKSH, the leading Market Expansion Services provider with a focus on Asia, signed an agreement with Aspen Malaysia, to drive sales of consumer health brands Dequadin and Cortal across Malaysia.
Kuala Lumpur, Malaysia, October 16, 2014 – DKSH Business Unit Consumer Goods, Asia’s leading Market Expansion Services specialist for Fast Moving Consumer Goods, has been appointed by Aspen Malaysia to provide marketing, sales and distribution services for its consumer health brands Dequadin and Cortal. The agreement includes retail channels in West and East Malaysia as well as Brunei.
Locally produced, Dequadin is one of Malaysia’s most popular throat lozenges and pastilles brands. Cortal is Aspen’s brand name for paracetamol. The company sees opportunities for growth in a wider range of retail channels including leading pharmacies, supermarkets, convenience stores, petrol marts and mini-markets nationwide.
“We selected DKSH for its extensive capillary distribution and its experience in driving sales for mature products. This partnership provides new opportunities for us to grow our business in the important Malaysian market. Outsourcing some of our activities to DKSH allows us to focus on our core competencies,” said Andrew Ooi, Country Manager, Aspen Malaysia.
“Aspen has built up a strong brand portfolio in the Malaysian market. We will leverage our network of unique scope and depth and marketing capabilities to further increase visibility and availability of the Dequadin and Cortal brands,” commented Lian Teng Hai, Executive Director, Business Unit Consumer Goods, DKSH Malaysia.
DKSH also provides Market Expansion Services for Dequadin in the pharmacy channel in Thailand. The new partnership will further strengthen DKSH’s market position in Malaysia while contributing incrementally to the Group’s overall profitability over time.
About Aspen Medical Products Malaysia Sdn Bhd Aspen Medical Products Malaysia Sdn Bhd is part of South Africa’s Aspen Group. Aspen Group is a leading generics supplier and manufacturer in the southern hemisphere and is Africa's largest pharmaceutical manufacturer. It is also ranked as Australia's number one generic pharmaceutical company. Aspen has 17 manufacturing facilities at 12 pharmaceutical manufacturing sites on six continents and approximately 6,000 employees.
15.10.2014 | DKSH, the leading Market Expansion Services provider with a focus on Asia, has signed an agreement with Roche to extend the duration of its decades-long partnership across Asian markets and expand it geographically.
Bangkok, Thailand, October 15, 2014 – DKSH Business Unit Healthcare, a leading partner for healthcare companies seeking to grow their business in Asia, will continue to provide Market Expansion Services for Roche’s full pharmaceutical product portfolio in Cambodia, Hong Kong, Laos, Malaysia, Myanmar, Singapore, Thailand and Vietnam.
DKSH is managing Roche’s entire supply chain operations for pharmaceutical products and distribution to hospitals, clinics and pharmacies in the region. It is the first time that DKSH and Roche work together in Singapore. In the other Asian markets, the agreement is a long-term extension of existing relationships that date back to as long as the 1940s.
“The extension of our agreement into new markets provides opportunities for Roche. DKSH is a reliable and professional partner that helps us grow our business across Asia, so that we can focus on our core business,” said Philippe Meyer, General Manager, Roche Thailand Limited.
“DKSH and Roche enjoy a long and successful collaboration. We are committed to utilize our in-depth healthcare expertise and network of unique scope and depth for growing Roche’s business in new and existing markets,” said Thomas Delemazure, Regional Business Development Director, DKSH Healthcare.
The agreement will further strengthen DKSH’s market position in the region while contributing incrementally to the Group’s overall profitability over time.
About Roche Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics and a frontrunner in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
In 2013 the Roche Group employed over 85,000 people worldwide, invested 8.7 billion Swiss francs in R&D and posted sales of 46.8 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
the company just show us one quarter of profit, the full financial year got 1.2mil loss, all people also scared to invest.. although 2014 financial year is the best result for them, everyone will still have to see whether the company income will be stable for the next few quarters.
DKSH extends partnership with Novo Nordisk in Malaysia 01.10.2014 | DKSH, the leading Market Expansion Services provider with a focus on Asia, signed an agreement to provide commercial and distribution services to Novo Nordisk, a global healthcare company with 90 years of experience in diabetes care, in Malaysia.
Kuala Lumpur, Malaysia, October 1, 2014 – DKSH Business Unit Healthcare, the leading partner for healthcare companies seeking to grow their business in Asia, has signed an agreement to provide marketing, sales and distribution services for Novo Nordisk’s NovoFine® insulin needles in pharmacy channels in Malaysia.
“DKSH’s commitment to quality and compliance as well as track record in the healthcare industry has made them our partner of choice. We are confident that this partnership will help strengthen NovoFine® insulin needles position in the pharmacy channels and give patients better access to our diabetic care products,” said Noha Shawky, General Manager, Novo Nordisk Pharma, Malaysia.
“We are pleased that Novo Nordisk has chosen DKSH to support NovoFine® insulin needles with our extensive commercial capabilities. The agreement reflects our strength, reputation and unrivalled capillary distribution network in the healthcare channels in Malaysia,” commented Dr. Marc Franck, Vice President Business Unit Healthcare, DKSH Malaysia.
DKSH already provides an integrated Market Expansion Services service portfolio that includes marketing and sales, distribution and logistics, credit management and collection services for Novo Nordisk’s entire product range to the hospital, clinic and pharmacy channels in Malaysia.
The new partnership will further strengthen DKSH’s market position in Malaysia while contributing incrementally to the Group’s overall profitability over time.
About Novo Nordisk Headquartered in Denmark, Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk employs approximately 40,700 employees in 75 countries, and markets its products in more than 180 countries.
Let me copy and paste this... Future prospects of NOVAMSC Group
The management of NOVAMSC views the market for NOVAMSC to be challenging due to uncertainties arising from global and domestic economic outlook and that NOVAMSC operates in a competitive industry that has many competitors and rising inflation, which may depress its profit margins. In spite of this, NOVAMSC is able to capitalise on the products and services it offers to establish a presence in the market. This is evidenced from the recent tender win for a project with the Legal Aid Bureau of Ministry of Law in Singapore ("LAB"), worth approximately RM24.5 million(approximately SGD9.6 million) consisting of a firm award of RM6.2 million for mandatory capital items, RM3.5 million for optional capital items and RM14.8 million for maintenance over 5 years subject to annual renewal. Over the years, NOVAMSC has amassed a track record in the e-Government and healthcare industries with a client portfolio which includes, amongst others, the Building and Construction Authority and Land Transport Authority of Singapore, Perbadanan Putrajaya in Malaysia and National Skin Centre and Singapore General Hospital of Singapore, Mahkota Hospital and Regency Specialists Hospital of Malaysia and EKA Hospital of Indonesia. In light of the Singaporean government’s announced initiatives to spur the ICT industry and to improve the overall utilisation of ICT in the government sector, NOVAMSC will be studying strategies to participate in them. Further, NOVAMSC intends to continue to expand its business internationally, into markets such as the Asia Pacific and Middle Eastern markets, subject to market and feasibility research to be conducted prior to its entry to the respective markets. The business expansion could be conducted by establishing strategic alliances with industry players or undertaking joint ventures in the targeted markets after taking the existing business environment of the targeted markets into consideration. As at the LPD, the Company is at the initial stage of venturing into the new markets, which includes preliminary studies being made on the potential markets. The management of NOVAMSC recognises that the future operating performance will be based on its ability to manage costs, increase operational efficiency and focused marketing strategies. The injection of funds from the Proposed Private Placement will aid NOVAMSC to improve its financial performance. (Source: Management of NOVAMSC)
1) Season Pass (Internet Plan) need more affordable package. 2) Tune Talk is the leader of MVNO. 3) There are competition from more than 5 other MVNOs eg. Tune Talk, Tron Prepaid, Buzz Me, Friendi, Speakout, Clixster , RedOne.....and Four MNO (Digi etc.) 4) Need advertise their XOX or Voopee product on television network, cinema etc. rather than having booth, numbers of my friend dun really know what is XOX and even Voopee. 5) There's no 4G..waiting for XOX to get it from Celcom. 6) RM6 needed to MNP to XOX. (price should be exempted) 7) Things they need to care, maintain and improve (Season Pass, Voopee, KKBOX, MNP(free) , XOX Rewards) 9) Mobile plan with smartphones packages (by using single-SIM smartphone not Dual-SIM to promote their SIM-FREE Voopee) 10) Must include Social Plan (For using FB, Twitter, Whatsapp, Voopee....) 11) More XOX Service Centre.
Joint Venture is not expected to have a material effect on the earnings per share, net assets and gearing of the Group for the financial year ending 30 June 2014 but is expected to contribute positively to the Group’s earnings and net assets in the future. Joint Venture is expected to be completed by the first quarter of the Group’s financial year ending 30 June 2015.
They have owned the Tuition centre for 70% stakes, just add 30% to fully control it?! Tuition centre only contribute minimal profits for the group except they expand it to few hundred centres all over Malaysia. Better to use their RM1.6mil to expand their MAA Cards business.